FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology and can be applied for treatment of malignant tumors, resistant to platinum-based medications. Method by invention includes introduction to patient of humanised antibody against 2C4 HER2 or its fragment, and chemical therapeutic medication of antimetabolite, each in amount, effective for treatment of malignant tumor.
EFFECT: application of invention allows to treat such tumors as malignant tumor of ovary, peritoneal carcinoma and carcinoma of Fallopian tubes, resistant to platinum-based medications, due to more active suppression by antibody 2C4 HER2 of HER dimerisation.
30 cl, 4 tbl, 6 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY | 2000 |
|
RU2270029C2 |
| HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
